Day One Earnings Estimate

DAWN Stock  USD 12.54  0.14  1.13%   
The next projected EPS of Day One is estimated to be -0.1971 with future projections ranging from a low of -0.3875 to a high of -0.055. Day One's most recent 12-month trailing earnings per share (EPS TTM) is at -0.97. Please be aware that the consensus of earnings estimates for Day One Biopharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
Day One is projected to generate -0.1971 in earnings per share on the 31st of December 2024. Day One earnings estimates show analyst consensus about projected Day One Biopharmaceuticals EPS (Earning Per Share). It derives the highest and the lowest estimates based on Day One's historical volatility. Many public companies, such as Day One, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm.

Day One Revenue Breakdown by Earning Segment

By analyzing Day One's earnings estimates, investors can diagnose different trends across Day One's analyst sentiment over time as well as compare current estimates against different timeframes. As of the 18th of January 2025, Gross Profit is likely to drop to about (361.9 K)
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Day One Biopharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

Day One Earnings Estimation Breakdown

The calculation of Day One's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Day One is estimated to be -0.1971 with the future projection ranging from a low of -0.3875 to a high of -0.055. Please be aware that this consensus of annual earnings estimates for Day One Biopharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
0.38
-0.39
Lowest
Expected EPS
-0.1971
-0.06
Highest

Day One Earnings Projection Consensus

Suppose the current estimates of Day One's value are higher than the current market price of the Day One stock. In this case, investors may conclude that Day One is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Day One's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of December 2024Current EPS (TTM)
1073.41%
0.38
-0.1971
-0.97

Day One Earnings per Share Projection vs Actual

Actual Earning per Share of Day One refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Day One Biopharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Day One, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Day One Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Day One, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Day One should always be considered in relation to other companies to make a more educated investment decision.

Day Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Day One's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-10-31
2024-09-30-0.25450.380.6345249 
2024-07-30
2024-06-30-0.75-0.050.793 
2024-05-06
2024-03-31-0.66-0.72-0.06
2024-02-26
2023-12-31-0.58-0.64-0.0610 
2023-11-06
2023-09-30-0.6-0.540.0610 
2023-08-07
2023-06-30-0.61-0.610.0
2023-05-01
2023-03-31-0.59-0.590.0
2023-03-06
2022-12-31-0.57-0.560.01
2022-11-07
2022-09-30-0.53-0.530.0
2022-08-04
2022-06-30-0.49-0.6-0.1122 
2022-05-12
2022-03-31-0.38-0.48-0.126 
2022-03-07
2021-12-31-0.36-0.360.0
2021-11-08
2021-09-30-0.28-0.33-0.0517 
2021-08-10
2021-06-30-0.31-5.04-4.731525 
2021-03-31
2020-12-310-5.9907-5.9907
2020-03-31
2019-12-310-0.672-0.672

About Day One Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Day One earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Day One estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Day One fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-412.7 M-392.1 M
Retained Earnings Total Equity-242.7 M-254.8 M
Earnings Yield(0.19)(0.18)
Price Earnings Ratio(5.55)(5.83)
Price Earnings To Growth Ratio(0.41)(0.43)

Pair Trading with Day One

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Day One position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Day One will appreciate offsetting losses from the drop in the long position's value.

Moving together with Day Stock

  0.71ME 23Andme HoldingPairCorr
  0.68VALN Valneva SE ADRPairCorr

Moving against Day Stock

  0.84DRTS Alpha Tau MedicalPairCorr
  0.7CDIOW Cardio DiagnosticsPairCorr
  0.68DMAC DiaMedica TherapeuticsPairCorr
  0.65VCEL Vericel Corp OrdPairCorr
  0.64VCYT Veracyte Potential GrowthPairCorr
The ability to find closely correlated positions to Day One could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Day One when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Day One - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Day One Biopharmaceuticals to buy it.
The correlation of Day One is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Day One moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Day One Biopharmaceu moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Day One can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Day One Biopharmaceu offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Day One's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Day One Biopharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Day One Biopharmaceuticals Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Day One Biopharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.97)
Revenue Per Share
1.144
Return On Assets
(0.25)
Return On Equity
(0.18)
The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Day One's value and its price as these two are different measures arrived at by different means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.